Mocetinostat

N-(2 -aminophenyl ) -4 - [(4- pyridin-3- yl -pyrimidin-2 -yl -amino) methyl] benzamide

Cytostatic

HDAC inhibitor

Template: Infobox chemical / molecular formula search available

Mocetinostat is a histone deacetylase inhibitor, currently, is in clinical trials for the treatment of various cancers, such as follicular lymphoma, Hodgkin's lymphoma and acute myeloid leukemia.

Medicinally the dihydrobromide salt used.

Pharmacology

Mechanism of Action

Mocetinostat Inhibits selectively histone 1,2,3 and 11, resulting in a hyperacetylation of histones in tumors. Then there will be an interruption in the cell cycle, for the expression of the P21 protein and subsequently to apoptosis of tumor cells.